Safe - SAFE

Safehold (NYSE:SAFE) Bolsa

SAFEHOLD INC

Safehold

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) today announced that it has received orders for its high-energy non-intrusive cargo and vehicle inspection systems valued at approximately $17 million USD from international customers. The systems will be placed at strategic locations securing sea and land ports.

News

Contracts

VREX

Varex Imaging Secures $17M Orders For High-Energy Cargo And Vehicle Inspection Systems From International Customers

Wells Fargo analyst Michael Sison maintains Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) with a Equal-Weight and raises the price target from $38 to $48.

Price Target

Analyst Ratings

NGVT

Wells Fargo Maintains Equal-Weight on Ingevity, Raises Price Target to $48

JMP Securities analyst Jordan Bender initiates coverage on Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Market Outperform rating and announces Price Target of $15.

Initiation

SGHC

JMP Securities Initiates Coverage On Super Group (SGHC) with Market Outperform Rating, Announces Price Target of $15

WIIM

RANI

Rani Therapeutics shares are trading higher after the company announced it has unveiled preclinical data at ENDO 2025 for the RaniPill capsule.

Grayscale Investments&#xAE; today announced that it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the "SEC"). The number of shares to be registered and the price range for the proposed registration have not yet been determined. The registration is expected to take place after the SEC completes its review process, subject to market and other conditions.

Offerings

GBTC

Grayscale Investments Files Confidential Draft Registration Statement With SEC For Potential Public Offering; No Size Or Amount Disclosed

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.
The trial included patients who were treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html" rel="noreferrer noopener">trial</a> showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" rel="noreferrer noopener">AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment</a>
The trial also met all secondary endpoints. Patients with uncontrolled or treatment-resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated and had a favourable safety profile.
There are 1.3 billion people worldwide living with hypertension. When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure, and kidney disease. In the U.S., approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.
The data will be shared with regulatory authorities worldwide and presented in a late‑breaking Hot Line session at the European Society of Cardiology (ESC) Congress&nbsp;in August 2025.
AstraZeneca acquired baxdrostat by purchasing CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash ($0.5 billion) is payable to former CinCor shareholders upon submitting a new drug application in the U.S. or Europe.
In related news, Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) recently received priority review from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46230333/mercks-hypertension-drug-on-fda-fast-track-for-label-expansion" rel="noreferrer noopener">Winrevair (sotatercept-csrk)</a>.
This application aims to update the U.S. product label based on compelling data from the Phase 3 ZENITH trial. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025.
In 2024, Winrevair was approved for adults with pulmonary arterial hypertension (PAH, Group 1 PH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
Price Action: AZN stock is trading higher by 0.60% to $71.57 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46387027/alibaba-bleeds-billions-as-delivery-price-war-erases-100-billion-in-market-value" target="_blank" rel="noreferrer noopener">Alibaba Bleeds Billions As Delivery Price War Erases $100 Billion In Market Value</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

Wells Fargo analyst Michael Sison maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $81 to $90.

Wells Fargo Maintains Overweight on DuPont de Nemours, Raises Price Target to $90

NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with <a href="https://www.globenewswire.com/Tracker?data=YXbNBFfgAsVdTtDothm2jIdMMfwCu1P_YBsPbn6Bx9rfv6SsL5ig3EsHn-tNOGOhTdcI8OJr6ag6Y0wCCAbhRH2JnfMUaAyAe3cdjIGmp0g=">STADA Arzneimittel AG</a> ("STADA"), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.
As part of the agreement, STADA will advance $1 million to NEXGEL in non-dilutive capital to support product launches and marketing efforts.

NXGL

NEXGEL Expands Partnership With STADA To Launch New Digestive And Skin Care Products, Receives $1M Non-Dilutive Funding

Offering to be led by Heights Capital Management, Inc., and will consist of ordinary shares sold at $4.00 per share, accompanied by warrants with an exercise price of $4.60.

LAES

SEALSQ Prices $60M Registered Direct Offering Of 15M Shares And Accompanying Warrants At Combined Price Of $4.00/Ordinary Share And Accompanying Warrants

Susquehanna analyst Mehdi Hosseini maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Positive and raises the price target from $255 to $265.

Susquehanna Maintains Positive on Taiwan Semiconductor, Raises Price Target to $265

DSYWW

Big Tree Cloud Regains Nasdaq Listing Compliance On MVPHS Rule

JMP Securities analyst Aaron Kimson initiates coverage on Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Market Outperform rating and announces Price Target of $58.

HNGE

JMP Securities Initiates Coverage On Hinge Health with Market Outperform Rating, Announces Price Target of $58

Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) (the "Company" or "Unusual Machines"), a leader in drone technology and component manufacturing, today announced it has entered into a securities purchase agreement with certain investors for the purchase and sale of 5,000,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering (the "Offering") at a public offering price of $9.70 per share.
Dominari Securities LLC is acting as the exclusive placement agent for the Offering.
The closing of the Offering is expected to occur on or about July 15, 2025, subject to the satisfaction of customary closing conditions.The Company expects to receive aggregate gross proceeds of $48.5 million from the Offering, before deducting placement agent fees and other related expenses. The Company intends to use the net proceeds from the Offering to support U.S.-based manufacturing expansion, working capital needs, and general corporate purposes.

UMAC

Unusual Machines Announces $48.5M Registered Direct Offering Of 5M Shares Or Pre-Funded Warrants At $9.70 Per Share, To Fund U.S. Manufacturing Expansion

Management

Rogers CEO Colin Gouveia Resigns; Ali El-Haj Appointed Interim President And CEO

Wells Fargo analyst Michael Sison maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Overweight and raises the price target from $66 to $72.

Wells Fargo Maintains Overweight on Celanese, Raises Price Target to $72

BON Regains Nasdaq Compliance

<a href="https://pr.report/c95q">WidePoint Corporation</a> (NYSE American:<a href="https://pr.report/c95r">WYY</a>), a leading provider of trusted identity, data, and cybersecurity solutions, is pleased to announce that it has been awarded a four-year contract, with a one-year base period and three one-year option periods. The contract was awarded under the Navy Spiral 4 Contract vehicle, positioning WidePoint as a trusted partner to the Defense Counterintelligence and Security Agency (DCSA).
This partnership highlights WidePoint's ongoing dedication to serving the federal government with tailored technology solutions that enhance security and efficiency.

WidePoint Awarded 4-Yr Contract Under Navy Spiral 4 Contract Vehicle, With One-Year Base Period And Three One-Year Option Periods

CLIK

Click Holdings shares are trading higher after the company announced it's eyeing a $100 million Bitcoin and Solana treasury.

Susquehanna analyst Charles Minervino maintains TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) with a Neutral and raises the price target from $1300 to $1600.

Susquehanna Maintains Neutral on TransDigm Gr, Raises Price Target to $1600

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has tapped $3 for the first time since January as renewed confidence in Ripple's expanding institutional utility and broader crypto market strength foreshadow new <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">potential all-time highs</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.94</td>
<td>&nbsp;$174.4 billion</td>
<td>+29.4%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$121,836.22</td>
<td>&nbsp;$2.4 trillion</td>
<td>+12.3%</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,043.40</td>
<td>&nbsp;$367.4 billion</td>
<td>+19.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Pentoshi called XRP's weekly close "strong" and sees the potential for new all-time highs as early as this week. 
If price discovery fully engages, he believes a move toward $4 or higher is on the table.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> weekly close is in $3 and ath&#39;s on deck quite possibly this week. Do not see any reason to be bearish on this price discovery could even lead to $4+ but before we talk about that, lets see new ath first <a href="https://t.co/v96afDxuDx">https://t.co/v96afDxuDx</a> <a href="https://t.co/ofUx8dVpDr">pic.twitter.com/ofUx8dVpDr</a>
&mdash; &#x1f427; Pentoshi (@Pentosh1) <a href="https://twitter.com/Pentosh1/status/1944560852264190090?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
DonAlt <a href="https://x.com/CryptoDonAlt/status/1944638834727072026">labeled</a> this as decision time, saying XRP is at a key inflection point. 
A successful breakout could lead to a significant upside run, while rejection here might cause a temporary pullback. 
Still, he notes momentum is with the bulls.
Statistics: Santiment <a href="https://x.com/santimentfeed/status/1943708549776879704">reported</a> the highest daily wallet creation (6,939 new addresses on July 11) since March 1. 
XRP also dominated online chatter, making up over 5.5% of all crypto-related discussions, the highest since March 18.
Coinglass data shows XRP open interest surged 12% to $8.3 billion — the highest since mid-January. 
Derivatives trading volume exploded by 64.6%, while liquidations hit $23.93 million, largely driven by shorts being wiped out.
Community News: ProShares XRP ETF is set to launch on July 18, following its <a href="https://www.dtcc.com/products/cs/exchange_traded_funds_plain_new.php">listing on the DTCC</a> earlier this week. 
Pro-Ripple attorney John Deaton <a href="https://x.com/JohnEDeaton1/status/1944540744678584328">called</a> it a milestone for the 75,000 XRP holders who fought for regulatory clarity and recognition of XRP as not a security.
Remittix, a cross-chain payment network, has <a href="https://www.globenewswire.com/news-release/2025/07/14/3114607/0/en/Remittix-Announces-XRP-Compatible-On-Ramp-Solution-as-Part-of-Cross-Border-Payment-Expansion.html">added</a> XRP to its fiat on-ramp options, joining Bitcoin, Ethereum, Dogecoin, and Solana. 
This move highlights growing institutional and retail demand for low-fee, high-utility digital assets.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46372617/xrp-explodes-for-25-weekly-gain-is-a-giga-rally-imminent">XRP Explodes For 25% Weekly Gain: Is A &#8216;Giga Rally&#8217; Imminent?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Safehold

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL